109. Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub2018 Feb 23.Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 yearsof tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised,phase 3 trial.De Placido S(1), Gallo C(2), De Laurentiis M(3), Bisagni G(4), Arpino G(1),Sarobba MG(5), Riccardi F(6), Russo A(7), Del Mastro L(8), Cogoni AA(5), CognettiF(9), Gori S(10), Foglietta J(11), Frassoldati A(12), Amoroso D(13), LaudadioL(14), Moscetti L(15), Montemurro F(16), Verusio C(17), Bernardo A(18), LorussoV(19), Gravina A(3), Moretti G(4), Lauria R(1), Lai A(5), Mocerino C(6), RizzoS(7), Nuzzo F(3), Carlini P(9), Perrone F(20); GIM Investigators.Collaborators: Accurso A, Agostara B, Aieta M, Alabiso O, Alicicco MG, Amadori D,Amaducci L, Amiconi G, Antuzzi G, Ardine M, Ardizzoia A, Aversa C, Badalamenti G,Barni S, Basurto C, Berardi R, Bergamasco C, Bidoli P, Bighin C, Biondi E,Bisagni G, Boni C, Borgonovo K, Botta M, Bravi S, Bruzzi P, Buono G, Butera A,Caldara A, Candeloro G, Cappelletti C, Cardalesi C, Carfora E, Cariello A,Carrozza F, Cartenì G, Caruso M, Casadei V, Casanova C, Castori L, Cavanna L,Cavazzini G, Cazzaniga M, Chilelli M, Chiodini P, Chiorrini S, Ciardiello F,Ciccarese M, Cinieri S, Clerico M, Coccaro M, Comande M, Corbo C, Cortino G,Cusenza S, Daniele G, D'arco AM, D'auria G, Dazzi C, De Angelis C, de Braud F, DeFeo G, De Matteis A, De Tursi M, Di Blasio A, di Lucca G, Di Lullo L, Di Rella F,Di Renzo G, Di Stefano P, Di Stefano A, Diana A, Donati S, Fabbri A, Fabi A,Faedi M, Farina G, Farris A, Febbraro A, Fedele P, Federico P, Ferraù F, FerrettiG, Ferro A, Floriani I, Forcignanò R, Forciniti S, Forestieri V, Fornari G,Frisinghelli M, Fusco V, Gallizzi G, Galvano A, Gambardella A, Gambi A, Gebbia V,Gervasi E, Ghilardi M, Giacobino A, Giardina G, Giotta F, Giraudi S, Giuliano M, Grassadonia A, Grasso D, Grosso F, Guizzaro L, Incoronato P, Incorvaia L, Iodice G, La Verde N, Labonia V, Landi G, Latorre A, Leonardi V, Levaggi A, Limite G,Lina Bascialla L, Livi L, Maiello E, Mandelli D, Marcon I, Menon D, Montedoro M, Moraca L, Moretti A, Morritti MG, Morselli P, Mura A, Mura S, Musacchio M, Muzio A, Natale D, Natoli C, Nigro C, Nisticò C, Nuzzo A, Orditura M, Orlando L,Pacilio C, Palumbo G, Palumbo R, Pasini F, Paterno E, Pazzola A, Pelliccioni S,Pensabene M, Perroni D, Pesenti Gritti A, Petrelli F, Piccirillo MC, Pinotti G,Pogliani C, Poli D, Prader S, Recchia F, Rizzi D, Romano C, Rossello R, RossiniC, Salvucci G, Sanna V, Santini A, Saracchini S, Savastano C, Scambia G,Schettini F, Schiavone P, Schirone A, Seles E, Signoriello S, Signoriello G,Silva RR, Silvestri A, Simeon V, Spagnoletti I, Tamberi S, Teragni C, Thalmann V,Thomas R, Thomas G, Tienghi A, Tinari N, Tinessa V, Tomei F, Tonini G, Torri V,Traficante D, Tudini M, Turazza M, Vignoli R, Vitale MG, Zacchia A, Zagarese P,Zanni A, Zavallone L, Zavettieri M, Zoboli A.Author information: (1)Dipartimento di Clinica Medica e Chirurgia, Università Federico II, Naples,Italy.(2)Statistica Medica, Università degli Studi della Campania Luigi Vanvitelli,Naples, Italy.(3)Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione Pascale,Istituto di Ricovero e Cura a Carattere Scientifico, Naples, Italy.(4)Dipartimento di Oncologia, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia,Italy.(5)Oncologia Medica, Azienda Ospedaliera Universitaria, Sassari, Italy.(6)Oncologia Medica, Ospedale Cardarelli, Naples, Italy.(7)Dipartimento di Scienze Chirurgiche, Oncologiche e Stomatologiche, Sezione di Oncologia Medica, Università di Palermo, Palermo, Italy.(8)Dipartimento di Medicina Interna e Specialità Mediche, Università degli Studi di Genova-Oncologia Medica, Ospedale Policlinico San Martino, Genoa, Italy.(9)Divisione Oncologia Medica 1, Istituto Nazionale Tumori Regina Elena, Rome,Italy.(10)Oncologia Medica, Ospedale Sacro Cuore Don Calabria, Negrar, Italy.(11)Oncologia Medica, Ospedale Silvestrini, Sant'Andrea delle Fratte, Italy.(12)Oncologia Clinica, Ospedale Sant'Anna di Cona, Ferrara, Italy.(13)Oncologia Medica, Ospedale della Versilia, Lido di Camaiore (LU), IstitutoToscano Tumori, Florence, Italy.(14)Oncologia Medica, Ospedale F Renzetti, Lanciano, Italy.(15)Dipartimento di Oncologia Medica, Ospedale Belcolle, Viterbo, Italy.(16)Divisione di Oncologia Clinica Investigativa dell'Istituto di Candiolo-IRCCS,Candiolo, Italy.(17)Oncologia Medica, ASST Valle Olona, Saronno, Italy.(18)Oncologia Medica, Fondazione S Maugeri IRCCS, Pavia, Italy.(19)Polo Oncologico, Ospedale Vito Fazzi, Lecce, Italy.(20)Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione Pascale,Istituto di Ricovero e Cura a Carattere Scientifico, Naples, Italy. Electronicaddress: f.perrone@istitutotumori.na.it.Erratum in    Lancet Oncol. 2018 Apr;19(4):e184.BACKGROUND: Uncertainty exists about the optimal schedule of adjuvant treatmentof breast cancer with aromatase inhibitors and, to our knowledge, no trial hasdirectly compared the three aromatase inhibitors anastrozole, exemestane, andletrozole. We investigated the schedule and type of aromatase inhibitors to beused as adjuvant treatment for hormone receptor-positive early breast cancer.METHODS: FATA-GIM3 is a multicentre, open-label, randomised, phase 3 trial of sixdifferent treatments in postmenopausal women with hormone receptor-positive earlybreast cancer. Eligible patients had histologically confirmed invasive hormonereceptor-positive breast cancer that had been completely removed by surgery, any pathological tumour size, and axillary nodal status. Key exclusion criteria were hormone replacement therapy, recurrent or metastatic disease, previous treatment with tamoxifen, and another malignancy in the previous 10 years. Patients wererandomly assigned in an equal ratio to one of six treatment groups: oralanastrozole (1 mg per day), exemestane (25 mg per day), or letrozole (2·5 mg per day) tablets upfront for 5 years (upfront strategy) or oral tamoxifen (20 mg per day) for 2 years followed by oral administration of one of the three aromataseinhibitors for 3 years (switch strategy). Randomisation was done by acomputerised minimisation procedure stratified for oestrogen receptor,progesterone receptor, and HER2 status; previous chemotherapy; and pathologicalnodal status. Neither the patients nor the physicians were masked to treatmentallocation. The primary endpoint was disease-free survival. The minimum cutoff todeclare superiority of the upfront strategy over the switch strategy was assumed to be a 2% difference in disease-free survival at 5 years. Primary efficacyanalyses were done by intention to treat; safety analyses included all patientsfor whom at least one safety case report form had been completed. Follow-up isongoing. This trial is registered with the European Clinical Trials Database,number 2006-004018-42, and ClinicalTrials.gov, number NCT00541086.FINDINGS: Between March 9, 2007, and July 31, 2012, 3697 patients were enrolledinto the study. After a median follow-up of 60 months (IQR 46-72), 401disease-free survival events were reported, including 211 (11%) of 1850 patients allocated to the switch strategy and 190 (10%) of 1847 patients allocated toupfront treatment. 5-year disease-free survival was 88·5% (95% CI 86·7-90·0) withthe switch strategy and 89·8% (88·2-91·2) with upfront treatment (hazard ratio0·89, 95% CI 0·73-1·08; p=0·23). 5-year disease-free survival was 90·0% (95% CI87·9-91·7) with anastrozole (124 events), 88·0% (85·8-89·9) with exemestane (148 events), and 89·4% (87·3 to 91·1) with letrozole (129 events; p=0·24). Nounexpected serious adverse reactions or treatment-related deaths occurred.Musculoskeletal side-effects were the most frequent grade 3-4 events, reported in130 (7%) of 1761 patients who received the switch strategy and 128 (7%) of 1766patients who received upfront treatment. Grade 1 musculoskeletal events were morefrequent with the upfront schedule than with the switch schedule (924 [52%] of1766 patients vs 745 [42%] of 1761 patients). All other grade 3-4 adverse events occurred in less than 2% of patients in either group.INTERPRETATION: 5 years of treatment with aromatase inhibitors was not superiorto 2 years of tamoxifen followed by 3 years of aromatase inhibitors. None of the three aromatase inhibitors was superior to the others in terms of efficacy.Therefore, patient preference, tolerability, and financial constraints should be considered when deciding the optimal treatment approach in this setting.FUNDING: Italian Drug Agency.Copyright © 2018 Elsevier Ltd. All rights reserved.DOI: 10.1016/S1470-2045(18)30116-5 PMID: 29482983 